Subjective cognitive impairment (SCI), Mild cognitive impairment (MCI)
Conditions
Interventions
Active group takes nobiletin-rich Chinpi extract daily for 24 weeks. The dosage is 1pack = 1g, 3 times a day before each meal. They take 3 g/day of the extract formulation, which contains 1,800 mg of
Sponsors
Tohoku University
1) Sendai Medical Imaging Clinic 2) Medical Imaging and Brain checkup Clinic
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Subjective cognitive impairment or mild cognitive impairment. (2) From 65 to 85 years old at the time of registration. (3) Regardless of gender. (4) Those who consent in writing to participate in this study. (5) Those who have cooperation from information providers about his/her daily life for this study. (6) Those who do not meet the exclusion criteria (see below).
Exclusion criteria
Exclusion criteria: (1) Already diagnosed with dementia or strongly suspected. (2) Already diagnosed with a neurodegenerative disease (e.g. Parkinson's disease) or suspected by interview or medical examination. (3) Affected to those physical condition by cerebrovascular disorders. (4) Currently taking the following medications within 1 month. ? Anti-dementia drug: donepezil, galantamine, rivastigmine (cholinesterase inhibitor) and memantine (NMDA receptor antagonist). ?Functional food and herbal medicines which claim that maintain cognitive function (e.g. phosphatidylserine, curcumin, ginkgo biloba extract and polygala root). ?Chinese herb preparations including Chinpi (e.g. Koso-san, Hei-san-san, Ni-chin-to, Tachibana-to, Tachibiki-to and Yokukan-san-Ken-saku). ?Central nervous system drugs (e.g. antidepressants, antipsychotics, anxiolytics, sleeping drugs, anti-parkinson drugs and psychostimulants). (5) Suspected of having metabolic encephalopathy (e.g. hepatic encephalopathy, renal encephalopathy, electrolyte abnormality and chronic obstructive pulmonary disease) by interview or medical examination. (6) Already diagnosed with mental illnesses (e.g. schizophrenia and depression) or suspected by an interview or examination. (7) Judged by the research doctor to be inappropriate. (8) An allergy history to Chinpi and citrus fruits. (9) Metals in the body such as pacemaker. (10) An allergy history to the FDG-PET tracer. (11) Obvious liver dysfunction, renal dysfunction, heart failure, severe anemia, severe malnutrition and inflammatory reaction.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in questionnaire about sense of forgetfulness (self-reported AD8) at the start of administration and after 24 weeks. | — |
Countries
Japan
Contacts
Public ContactTomonari Koto
New Industry Creation Hatchery Center (NICHe), Tohoku University Geriatric Behavioral Neurology Project
Outcome results
None listed